Dr. Kudo on Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib

Masatoshi Kudo, MD, PhD
Published: Sunday, Sep 16, 2018



Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib (Lenvima) versus sorafenib in unresectable hepatocellular carcinoma (HCC) in Japan.

Using data from the phase III REFLECT clinical trial, Kudo and colleagues developed a partitioned survival model to estimate the cost to treat Japanese patients with HCC over a lifetime horizon, taking into consideration indirect costs, such as hospital admissions, to the Japanese healthcare system. Data showed that lenvatinib confers a greater benefit in terms of quality-adjusted life years (QALYs)—at a lower cost—than does sorafenib.

It is a rare scenario in which a new drug provides greater benefit in QALYs with a lower cost than the standard of care, and the results of the analysis suggest that lenvatinib can provide a benefit not only to patients, but also to the healthcare system as a whole, Kudo concludes.

View more from the 2018 International Liver Cancer Association Annual Conference

Brought to you in part by Eisai


Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib (Lenvima) versus sorafenib in unresectable hepatocellular carcinoma (HCC) in Japan.

Using data from the phase III REFLECT clinical trial, Kudo and colleagues developed a partitioned survival model to estimate the cost to treat Japanese patients with HCC over a lifetime horizon, taking into consideration indirect costs, such as hospital admissions, to the Japanese healthcare system. Data showed that lenvatinib confers a greater benefit in terms of quality-adjusted life years (QALYs)—at a lower cost—than does sorafenib.

It is a rare scenario in which a new drug provides greater benefit in QALYs with a lower cost than the standard of care, and the results of the analysis suggest that lenvatinib can provide a benefit not only to patients, but also to the healthcare system as a whole, Kudo concludes.

View more from the 2018 International Liver Cancer Association Annual Conference

Brought to you in part by Eisai

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x